<DOC>
	<DOCNO>NCT01229839</DOCNO>
	<brief_summary>TACE consider standard treatment unresectable HCC basis fact alternative curative procedures.But optimal combine regimen still unclear . One controversy protocol contain lipiodo executer . The investigator hypothesize TACE without mix chemotherapy lipiodol unacceptably bad TACE mix chemotherapy lipiodol .</brief_summary>
	<brief_title>Chemoembolization With Without Mixing Chemotherapy With Lipiodol Unresectable HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Eligibility criterion : Adults patient diagnosis HCC amenable surgical resection , local ablative therapy cure treatment . Patients must least one tumor lesion accurately measure accord EASL criterion . And lesion previously treat TACE , surgery , radiation therapy , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . No serious concurrent medical illness Unresectable BCLC stage AB disease No cirrhosis cirrhotic status ChildPugh class A No significant renal impairment ( creatinine clearance &lt; 30 mL/minute ) patient dialysis No current infection require antibiotic therapy Not anticoagulation suffer know bleed disorder No unstable coronary artery disease recent MI The following laboratory parameter : Platelet count ≥ 60,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L ASL AST ≤ 5 x upper limit normal Serum creatinine ≤ 1.5 x upper limit normal INR ≤ 1.5 PT/APTT within normal limit Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Ability understand protocol agree sign write informed consent document Known history HIV History organ allograft Pregnant breastfeed patient Known suspected allergy investigational agent agent give association trial . Cardiac ventricular arrhythmia require antiarrhythmic therapy Evidence bleeding diathesis . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug Serious nonhealing wound , ulcer , bone fracture Known central nervous system tumor include metastatic brain disease severe Arterioportal Shunts Arteriavein Shunts</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Chemoembolization ,</keyword>
	<keyword>TACE</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Iodized Oil/administration &amp; dosage</keyword>
	<keyword>polyvinyl alcohol</keyword>
	<keyword>Humans</keyword>
</DOC>